USD 4.52
(-9.57%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 2.82 Million USD | 18.38% |
2022 | 2.38 Million USD | -7.78% |
2021 | 2.58 Million USD | 271.47% |
2020 | -1.5 Million USD | -84.68% |
2019 | -816 Thousand USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 34 Thousand USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 2.74 Million USD | -2.84% |
2024 Q2 | 1.64 Million USD | -40.02% |
2023 FY | 2.82 Million USD | 18.38% |
2023 Q2 | 3.42 Million USD | -2.7% |
2023 Q1 | 3.51 Million USD | 47.5% |
2023 Q3 | 3.26 Million USD | -4.5% |
2023 Q4 | 2.82 Million USD | -13.63% |
2022 Q1 | 1.9 Million USD | -26.2% |
2022 FY | 2.38 Million USD | -7.78% |
2022 Q4 | 2.38 Million USD | 29.86% |
2022 Q3 | 1.83 Million USD | -46.97% |
2022 Q2 | 3.46 Million USD | 81.44% |
2021 Q1 | - USD | 100.0% |
2021 Q3 | 1.00 USD | 0.0% |
2021 Q4 | 2.58 Million USD | 258399900.0% |
2021 FY | 2.58 Million USD | 271.47% |
2021 Q2 | - USD | 0.0% |
2020 Q1 | -1.78 Million USD | 0.11% |
2020 FY | -1.5 Million USD | -84.68% |
2020 Q3 | -1.71 Million USD | -6.72% |
2020 Q4 | -2.06 Million USD | -20.42% |
2020 Q2 | -1.6 Million USD | 10.03% |
2019 Q4 | -1.78 Million USD | -121.71% |
2019 FY | -816 Thousand USD | 0.0% |
2019 Q1 | -1.76 Million USD | -11.19% |
2019 Q2 | -1.58 Million USD | 10.12% |
2019 Q3 | 8.23 Million USD | 618.06% |
2018 Q2 | -589 Thousand USD | 31.59% |
2018 FY | - USD | 0.0% |
2018 Q4 | -1.59 Million USD | -117.21% |
2018 Q1 | -861 Thousand USD | -0.82% |
2018 Q3 | -732 Thousand USD | -24.28% |
2017 Q1 | -1.54 Million USD | -64.22% |
2017 Q3 | -802 Thousand USD | -9.12% |
2017 Q4 | -854 Thousand USD | -6.48% |
2017 FY | - USD | 0.0% |
2017 Q2 | -735 Thousand USD | 52.33% |
2016 Q2 | -981 Thousand USD | -49.32% |
2016 FY | - USD | 0.0% |
2016 Q1 | -657 Thousand USD | -41.6% |
2016 Q4 | -939 Thousand USD | -20.69% |
2016 Q3 | -777.99 Thousand USD | 20.69% |
2015 Q1 | -215 Thousand USD | -7.5% |
2015 FY | - USD | 0.0% |
2015 Q4 | -463.99 Thousand USD | 82.11% |
2015 Q3 | -2.59 Million USD | -609.43% |
2015 Q2 | 509 Thousand USD | 336.74% |
2014 Q3 | -88.99 Thousand USD | -122.31% |
2014 Q1 | 580 Thousand USD | 1605.88% |
2014 FY | - USD | -100.0% |
2014 Q4 | -200 Thousand USD | -124.72% |
2014 Q2 | 399 Thousand USD | -31.21% |
2013 Q4 | 34 Thousand USD | 158.62% |
2013 Q2 | - USD | 0.0% |
2013 Q1 | - USD | 100.0% |
2013 FY | 34 Thousand USD | 0.0% |
2013 Q3 | -58 Thousand USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | -30.99 Thousand USD | 0.0% |
2011 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | 76.539% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | 85.212% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 95.274% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | 70.936% |
bluebird bio, Inc. | 22.91 Million USD | 87.691% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 99.269% |
Myriad Genetics, Inc. | 20.1 Million USD | 85.965% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 92.634% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 96.356% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.966% |
Waters Corporation | 516.23 Million USD | 99.454% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.945% |
Biogen Inc. | 2.52 Billion USD | 99.888% |
Nektar Therapeutics | 16.1 Million USD | 82.479% |
Perrigo Company plc | 1.14 Billion USD | 99.753% |
Dynavax Technologies Corporation | 53.29 Million USD | 94.706% |
Illumina, Inc. | 587 Million USD | 99.519% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | 72.802% |
Heron Therapeutics, Inc. | 42.11 Million USD | 93.301% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 99.745% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | 74.35% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.891% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 95.701% |
FibroGen, Inc. | 41.56 Million USD | 93.213% |
Agilent Technologies, Inc. | 1.03 Billion USD | 99.726% |
OPKO Health, Inc. | 65.69 Million USD | 95.706% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 96.836% |
Exelixis, Inc. | 17.32 Million USD | 83.715% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 99.89% |
Axsome Therapeutics, Inc. | 15.13 Million USD | 81.361% |
Abeona Therapeutics Inc. | -2.44 Million USD | 215.426% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 99.618% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 90.076% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 99.126% |
Corcept Therapeutics Incorporated | 7.73 Million USD | 63.506% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 97.789% |
Blueprint Medicines Corporation | 21.22 Million USD | 86.708% |
Insmed Incorporated | 83.24 Million USD | 96.611% |
TG Therapeutics, Inc. | 39.82 Million USD | 92.916% |
Incyte Corporation | 62.97 Million USD | 95.52% |
Emergent BioSolutions Inc. | 328.9 Million USD | 99.142% |